Impact of edoxaban approval for venous thromboembolism on length of hospitalization

Abstract: Background: The direct anti-Xa agent edoxaban was approved in September 2014 as an alternative to warfarin for treatment of venous thromboembolism (VTE). Methods and Results: The advantages of edoxaban for VTE treatment were assessed by comparing the in-hospital clinical courses of 79 consecutive patients before and after edoxaban approval. Edoxaban was frequently used soon after its approval for VTE. The median length of hospitalization was significantly shorter after than before edoxaban approval (12.0 vs 17.0 days, respectively; p<0.01). Conclusion: Treatment with edoxaban may significantly shorten the length of hospitalization in patients with VTE compared with standard care with warfarin.